BlackRock discloses 5.4% stake in Maze Therapeutics
BlackRock, Inc. reports a passive ownership stake in Maze Therapeutics Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. reports a passive ownership stake in Maze Therapeutics Inc. common stock. BlackRock and certain of its subsidiaries and affiliates beneficially own 2,978,114 shares of Maze common stock, representing 5.4% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,922,889 shares and sole dispositive power over all 2,978,114 shares, with no shared voting or dispositive power. Various underlying clients and funds have rights to dividends or sale proceeds from these securities, but no single client holds more than five percent of Maze’s total outstanding common shares.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
Investment Company Act of 1940 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MAZE common stock does BlackRock, Inc. report owning?
What dispositive power does BlackRock report over MAZE stock?
Do any BlackRock clients individually own over 5% of MAZE?
Who signed the BlackRock ownership report for MAZE (ticker MAZE)?
AI-generated analysis. How Rhea-AI works. Not financial advice.